Emerging investigations on retatrutide, a dual agonist for incretin hormone and glucose-dependent insulinotropic polypeptide, suggest promising results in treating weight gain and type 2 diabetes. Initial data from clinical experiments show notable reductions in body mass and improved glucose reg